Table of contents
19 April 2017
Regulome networks and mutational landscape in liver cancer: An informative path to precision medicine
Song Yi, Nidhi Sahni – 19 April 2017
Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction
Paula Cox‐North, Kelsey L. Hawkins, Sean T. Rossiter, Marie N. Hawley, Renuka Bhattacharya, Charles S. Landis – 18 April 2017 – Sofosbuvir (SOF) is a nonstructural 5B polymerase inhibitor with activity in all hepatitis C virus (HCV) genotypes and is the backbone of many anti‐HCV drug regimens. SOF is converted into inactive metabolites that undergo renal excretion.
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
Jerry R. Colca, William G. McDonald, Kyle S. McCommis, Brian N. Finck – 18 April 2017 – Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193‐197)
Same policy, different impact: Center‐level effects of share 35 liver allocation
Douglas R. Murken, Allison W. Peng, David D. Aufhauser, Peter L. Abt, David S. Goldberg, Matthew H. Levine – 13 April 2017 – Early studies of national data suggest that the Share 35 allocation policy increased liver transplants without compromising posttransplant outcomes. Changes in center‐specific volumes and practice patterns in response to the national policy change are not well characterized. Understanding center‐level responses to Share 35 is crucial for optimizing the policy and constructing effective future policy revisions.
The Riddle of Juvenile Sclerosing Cholangitis
Giorgina Mieli‐Vergani, Diego Vergani – 13 April 2017
Coil‐assisted retrograde transvenous obliteration and partial splenic artery embolization for hepatic encephalopathy
Frank Kuo, Jonathan Park, Alice Chen – 13 April 2017
Thomas E. Starzl, M.D., Ph.D. (1926–2017)
Jorge Rakela, John J. Fung – 13 April 2017
Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review
Bruno Sangro, Diego Martínez‐Urbistondo, Lourens Bester, Jose I. Bilbao, Douglas M. Coldwell, Patrick Flamen, Andrew Kennedy, Jens Ricke, Ricky A. Sharma – 13 April 2017 – Selective internal radiation therapy (or radioembolization) by intra‐arterial injection of radioactive yttrium‐90‐loaded microspheres is increasingly used for the treatment of patients with liver metastases or primary liver cancer. The high‐dose beta‐radiation penetrates an average of only 2.5 mm from the source, thus limiting its effects to the site of delivery.
Extracellular vesicles from bone marrow–derived mesenchymal stem cells protect against murine hepatic ischemia/reperfusion injury
Hiroaki Haga, Irene K. Yan, David A. Borrelli, Akiko Matsuda, Mansi Parasramka, Neha Shukla, David D. Lee, Tushar Patel – 13 April 2017 – Hepatic ischemia/reperfusion injury (IRI) and associated inflammation contributes to liver dysfunction and complications after liver surgery and transplantation. Mesenchymal stem cells (MSCs) have been reported to reduce hepatic IRI because of their reparative immunomodulatory effects in injured tissues. Recent studies have highlighted beneficial effects of extracellular vesicles from mesenchymal stem cells (MSC‐EV) on tissue injury.